2',3'-O-Isopropylidene 5-hydroxyuridine manufacturers
|
| | 2',3'-O-Isopropylidene 5-hydroxyuridine Basic information |
| Product Name: | 2',3'-O-Isopropylidene 5-hydroxyuridine | | Synonyms: | 2',3'-O-Isopropylidene 5-hydroxyuridine;5-Hydroxy-2',3'-O-(1-methylethylidene)uridine;2',3'-Di-O-isopropylidene 5-hydroxyuridine;2',3'-Isopropylidene-5-hydroxyuridine;Uridine, 5-hydroxy-2',3'-O-(1-methylethylidene)-;5-hydroxy-1-((3aR,4R,6R,6aR)-6-(hydroxymethyl)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)pyrimidine-2,4(1H,3H)-dione;2’,3’-Isopropylidene-5-hydroxyuridine | | CAS: | 20406-82-0 | | MF: | C12H16N2O7 | | MW: | 300.27 | | EINECS: | | | Product Categories: | | | Mol File: | 20406-82-0.mol |  |
| | 2',3'-O-Isopropylidene 5-hydroxyuridine Chemical Properties |
| density | 1.489±0.06 g/cm3(Predicted) | | pka | 8.62±0.20(Predicted) |
| | 2',3'-O-Isopropylidene 5-hydroxyuridine Usage And Synthesis |
| Uses | 2’,3’-Isopropylidene-5-hydroxyuridine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
| | 2',3'-O-Isopropylidene 5-hydroxyuridine Preparation Products And Raw materials |
|